Effectiveness of catch‐up and routine program of the 9‐valent vaccine on cervical cancer risk reduction in Japan
Cancer Science · 2024-03 · 115 (3) · 916-925
DOI: 10.1111/cas.16055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 30.12.2023. Verfasst von Asami Yagi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: A Health and Labour Sciences Research Grant.
Abstract (Originalsprache)
In 2013, the national human papillomavirus (HPV) immunization program began. However, in June 2013, Japan's Ministry of Health, Labor and Welfare (MHLW) announced a “temporary” suspension of its recommendation for the human papillomavirus vaccine. Finally, in November 2021, the MHLW ended its suspension of the recommendation of the HPV vaccine. To address the 9‐year gap in HPV vaccinations the suspension had caused, the MHLW conducted a program of catch‐up vaccinations from April 2022 to March 2025. Finally, in April 2023, the 9‐valent HPV vaccine was approved for both the routine and catch‐up vaccination programs in Japan. In this study, we investigated the potential effects of the introduction of the 9‐valent vaccine on the increased risk of cervical cancer in females born after fiscal year (FY) 2000. We estimated the lifetime relative risk of cervical cancer incidence and death using the improved routine and catch‐up vaccination rates after the recent resumption of the governmental recommendation for women and girls to have the HPV vaccination. These relative risks were calculated using a lifetime risk of 1.000 for cervical cancer incidence and death for females born in FY 1993. We predicted that even if a 90% vaccination rate were to be achieved by FY 2024 with the 9‐valent vaccine among women born between FY 2000 and FY 2005, the risk would remain higher than for the vaccination generation. Therefore, for women born between FY 2000 and FY 2005, it will be necessary to significantly improve the cervical cancer screening rate to compensate for this increased risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Oita, Japan.
- Department of Obstetrics and Gynecology, Oita University Graduate School of Medicine, Ufu, Oita, Japan.
- Faculty of Informatics, Gunma University, Maebashi, Gunma, Japan.
- Clinical Psychology, Graduate School of Human Sciences, Osaka University, Osaka, Japan.
- Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
ORCID-Profile: Asami Yagi, Sayaka Ikeda, Yuri Ito, Tomio Nakayama
Förderung
- A Health and Labour Sciences Research Grant
Zitieren
APA
Yagi, A., Nakagawa, S., Ueda, Y., Oka, E., Ikeda, S., Kakuda, M., Kobayashi, E., Ito, Y., Katayama, K., Hirai, K., Nakayama, T., & Kimura, T. (2024). Effectiveness of catch‐up and routine program of the 9‐valent vaccine on cervical cancer risk reduction in Japan. Cancer Science, 115(3), 916-925. https://doi.org/10.1111/cas.16055
Vancouver
Yagi A, Nakagawa S, Ueda Y, Oka E, Ikeda S, Kakuda M, et al. Effectiveness of catch‐up and routine program of the 9‐valent vaccine on cervical cancer risk reduction in Japan. Cancer Science. 2024;115(3):916-925. doi:10.1111/cas.16055
BibTeX
@article{Yagi2024,
author = {Yagi, Asami and Nakagawa, Satoshi and Ueda, Yutaka and Oka, Emiko and Ikeda, Sayaka and Kakuda, Mamoru and Kobayashi, Eiji and Ito, Yuri and Katayama, Kayoko and Hirai, Kei and Nakayama, Tomio and Kimura, Tadashi},
title = {Effectiveness of catch‐up and routine program of the 9‐valent vaccine on cervical cancer risk reduction in Japan},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {3},
pages = {916--925},
doi = {10.1111/cas.16055}
}
EUVIMED